Publications by authors named "C Fleurinck"
Objective: To assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).
Methods: Patients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16.
Background: Fatigue is an important symptom for most patients with axial spondyloarthritis (axSpA). The FACIT-Fatigue is a 13-item patient-reported outcome (PRO) instrument that has been used in axSpA clinical trials to measure fatigue severity and impact on daily activities. However, the psychometric properties of the FACIT-Fatigue are not fully evaluated across the entire spectrum of axSpA including non-radiographic axSpA (nr-axSpA) and radiographic axSpA (r-axSpA).
View Article and Find Full Text PDFArticle Synopsis
- Acute anterior uveitis is a common issue in patients with axial spondyloarthritis, and IL-17 plays a role in its development, but there's mixed evidence on how well IL-17A inhibitors work in treating it.
- This study pooled data from various clinical trials comparing the effects of bimekizumab (a monoclonal antibody that targets both IL-17A and IL-17F) and a placebo on the incidence of uveitis.
- Results showed that patients on bimekizumab had a significantly lower rate of uveitis compared to those receiving placebo, suggesting that bimekizumab may provide protective effects against uveitis in these patients.
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
RMD Open
June 2024
Article Synopsis
- The study aimed to evaluate the effects of bimekizumab on physical function, sleep quality, work productivity, and overall health-related quality of life in patients with non-radiographic and radiographic axial spondyloarthritis. !* -
- Patients were randomly assigned to receive either bimekizumab or a placebo, with significant improvements observed in physical functioning and quality of life measures at Week 16, which were maintained or improved by Week 52. !* -
- The findings suggest that bimekizumab can provide early and sustained benefits across various aspects of health and well-being for patients with axial spondyloarthritis. !*
Article Synopsis
- The study aimed to evaluate how meeting specific clinical response criteria affects patient-reported outcomes in individuals with non-radiographic and radiographic axial spondyloarthritis after 52 weeks.
- It found that patients who achieved higher levels of clinical response (like ASAS40) experienced significantly greater improvements in core health areas such as pain, fatigue, and overall functioning compared to those with lower responses.
- The findings indicated that similar levels of improvement were seen in both non-radiographic and radiographic patients, suggesting effective treatment across different stages of the disease.